47
Participants
Start Date
May 14, 2018
Primary Completion Date
July 31, 2027
Study Completion Date
December 31, 2027
Tumor Infiltrating Lymphocytes (TIL)
TIL infusion intravenously through a central vein catheter over 20-30 minutes. Folowed by Aldesleukin, administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of TIL infusion and continuing for up to a maximum of 6 doses.
RECRUITING
UPMC Hillman Cancer Center, Pittsburgh
Udai Kammula
OTHER